Progress in the therapy of small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 2, 2004, Pages 119-133

  Simon, Miklos ^a   Argiris, Athanassios ^b   Murren, John R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Prophylactic cranial irradiation; Radiation therapy; Small cell lung cancer

Indexed keywords

AMRUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BCG VACCINE; BEC 2 ANTIBODY; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3 ANTIBODY; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; OBLIMERSEN; PACLITAXEL; PLATINUM DERIVATIVE; TANOMASTAT; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALOPECIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TOLERABILITY; ESOPHAGITIS; HUMAN; INFECTION; INFLAMMATION; LEUKOPENIA; LUNG SMALL CELL CANCER; META ANALYSIS; MUSCULOSKELETAL DISEASE; NEUTROPENIA; PNEUMONIA; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; SIDE EFFECT; SKULL IRRADIATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0842263747     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00118-5     Document Type: Review

References (127)

1. Page N.C., Read W.L., Tierney R.M., Arquette M.A., Piccirillo J.F., Govindan R. The epidemiology of small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. 2002;A 1216.
2. Ettinger D.S. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin. Oncol. 28:(Suppl. 4):2001;27-29.
3. Sandler A.B. Current management of small cell lung cancer. Semin. Oncol. 24:1997;463-476.
4. Murren J.R., Glatstein E., Pass H.I. Small cell lung cancer. DeVita V.T. Jr, Hellman S., Rosenberg S.A. Cancer principles and practice of oncology. 6th ed:2001;983-1018 Lippincott Williams & Wilkins, Philadelphia.
5. Janne P.A., Freidlin B., Saxman S., et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 95:2002;1528-1538.
6. Green R.A., Humphrey E., Close H., Patno M.E. Alkylating agents in bronchogenic carcinoma. Am. J. Med. 46:1969;516-525.
7. Lowenbraun S., Bartolucci A., Smalley R.V., Lynn M., Krauss S., Durant J.R. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer. 44:1979;406-413.
8. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br. J. Cancer. 40:1979;1-10.
9. Argiris A., Murren J.R. Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents. Cancer J. 7:2001;228-235.
10. Roth B.J., Johnson D.H., Einhorn L.H., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 10:1992;282-291.
11. Ettinger D.S., Finkelstein D.M., Sarma R.P., Johnson D.H. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 13:1995;1430-1435.
12. Ferri W.J., Garfield D., Neubauer M., Gregurich M.L. A. A phase II study of weekly paclitaxel (Taxol®) followed by carboplatin and etoposide in the treatment of extensive small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;259b.
13. Thomas P., Castelnau O., Paillotin D., et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J. Clin. Oncol. 19:2001;1320-1325.
14. Nair S., Marschke R., Grill J., et al. A phase II study of paclitaxel and cisplatin in the treatment of extensive stage small celll lung cancer. Proc. Am. Soc. Clin. Oncol. 16:1997;454a.
15. Hainsworth J.D., Gray J.R., Stroup S.L., et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J. Clin. Oncol. 15:1997;3464-3470.
16. Mavroudis D., Papadakis E., Veslemes M., et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer. Ann. Oncol. 12:2001;463-470.
17. Niell H.B., Herndon J.E., Miller A.A., et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). Proc. Am. Soc. Clin. Oncol. 2002;A 1169.
18. Birch R., Greco F.A., Hainsworth J., et al. Preliminary results of a randomized study comparing etoposide and carboplatin (EP) with or without paclitaxel (T) in newly diagnosed small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 2000;A 1260.
19. Hesketh P.J., Crowley J.J., Burris H.A. III, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J. Sci. Am. 5:1999;237-241.
20. Lianes P., Moreno-Nogueira J.A., Cardenal F., et al. Multicenter phase II clinical trial of docetaxel (D) in combination with cisplatin (P) in first-line chemotherapy for small-cell lung cancer (SCLC) extensive disease: final results. Proc. Am. Soc. Clin. Oncol. 20:2001;282b.
21. Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 5:1994;283-285.
22. Israel V.P., Chansky K., Gandara D. Southwest Oncology Group Trial (SWOG) S9718: a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer (E-SCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;316a.
23. Rassmann I., Thodtmann R., Depenbrock H. Gemcitabine and etoposide in small-cell lung cancer: phase I and II trials. Semin. Oncol. 24:1997;75-78.
24. Vansteenkiste J., Gatzemeier U., Manegold C., et al. Gemcitabine plus etoposide in chemonaive extensive disease small-cell lungcancer: a multi-centre phase II study. Ann. Oncol. 12:2001;835-840.
25. James L.E., Rudd R., Gower N.H., et al. A phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 2002;A 1170.
26. Schiller J.H., Kim K., Hutson P., et al. Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 14:1996;2345-2352.
27. Schiller JH, Adak S, Cella III D, DRF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group, J Clin Oncol 2001;19:2114-22.
28. Tweedy C.R., Andrews D.F., Ball T. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy. Proc. Am. Soc. Clin. Oncol. 18:1999;525a.
29. Lynch T.J., Herndon J.E., Lyss A.P., et al. Paclitaxel (P)+topotecan (T)+GCSF for previously untreated extensive small cell lung cancer (E-SCLC): preliminary analysis of cancer and leukemia group B (CALGB) 9430. Proc. Am. Soc. Clin. Oncol. 19:2000;491a.
30. Jett J.R., Bernath A.M. Jr, Hillman S.L., et al. Oral topotecan and paclitaxel with G-CSF support in patients with untreated extensive stage small cell (ED-SCLC): a phase II trial of the NCCTG. Proc. Am. Soc. Clin. Oncol. 2002;A 1301.
31. Frasci G., Nicolella G., Comella P., et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Br. J. Cancer. 84:2001;1166-1171.
32. Ohe Y., Saijo N. Topoisomerase I targeting agents in small-cell lung cancer. Curr. Oncol. Rep. 3:2001;170-178.
33. Negoro S., Fukuoka M., Niitani H., et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho. 18:1991;1013-1019.
34. Kudoh S., Fujiwara Y., Takada Y., et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol. 16:1998;1068-1074.
35. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl. J. Med. 346:2002;85-91.
36. Kinoshita A., Fukuda M., Fukuda M., et al. A phase II study of irinotecan (CPT-11) and carboplatin (CBDCA) in patients (pts) with small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 2002;A 1260.
37. Nakamura S., Kudoh S., Komuta K., Nakano T., Fukuoka M., Ariyoshi Y. Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small-cell lung cancer (ED-SCLC): a study of the West Japan Lung Cancer Group. Proc. Am. Soc. Clin. Oncol. 18:1999;470a.
38. Higano C.S., Crowley J.J., Veith R.V., Livingston R.B. A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. Invest. New Drugs. 15:1997;153-156.
39. Gridelli C., Perrone F., Ianniello G.P., et al. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J. Clin. Oncol. 16:1998;1414-1419.
40. Hanada M., Mizuno S., Fukushima A., Saito Y., Noguchi T., Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn. J. Cancer Res. 89:1998;1229-1238.
41. Negoro T., Takada Y., Yokota S. Phase II study of amrubicin (SM-5887), a 9-amino-anthracyclin in previously untreated patients with extensive stage small cell cancer (ES SCLC): a West Japan Lung Cancer Group trial. Proc. Am. Soc. Clin. Oncol. 17:1998;450c.
42. Ebi N., Kubota K., Nishiwaki Y., et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn. J. Clin. Oncol. 27:1997;166-169.
43. Fukuoka M., Furuse K., Saijo N., et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl. Cancer Inst. 83:1991;855-861.
44. Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 15:1997;2090-2096.
45. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 17:1999;658-667.
46. von Pawel J., Gatzemeier U., Pujol J.L., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J. Clin. Oncol. 19:2001;1743-1749.
47. Baker S.D., Heideman R.L., Crom W.R., Kuttesch J.F., Gajjar A., Stewart C.F. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol. 37:1996;195-202.
48. Herben V.M.M., Ten Bokkel Huinink W.W., Beijnen J.H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 31:1996;85-102.
49. Korfel A., Oehm C., von Pawel J., et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. A multicentre phase II study. Eur. J. Cancer. 38:2002;1724-1729.
50. Masuda N., Fukuoka M., Kusunoki Y., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10:1992;1225-1229.
51. Le Chevalier T., Ibrahim N., Chomy P., et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line treatment. Proc. Am. Soc. Clin. Oncol. 16:1997;450a.
52. Masuda N., Matsui K., Negoro S., et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 16:1998;3329-3334.
53. Naka N., Kawahara M., Okishio K., et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer. 37:2002;319.
54. Smyth J.F., Smith I.E., Sessa C., et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur. J. Cancer. 30A:1994;1058-1060.
55. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br. J. Cancer. 77:1998;347-351.
56. Dómine M., Gonzalez Larriba J.L.G., Morales S., et al. Gemcitabine and paclitaxel as second line treatment in small cell lung cancer (SCLC). A Multicentric Phase II Study. Proc. Am. Soc. Clin. Oncol. 20:2001;317a.
57. Groen H.J., Fokkema E., Biesma B., et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J. Clin. Oncol. 17:1999;927-932.
58. Van der Lee I., Smit E.F., van Putten J.W.G., et al. Single agent gemcitabine in patients with resistant small cell lung cancer. Ann. Oncol. 12:2001;557-561.
59. Jassem J., Karnicka-Mlodkowska H., van Pottelsberghe C., et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur. J. Cancer. 12:1993;1720-1722.
60. Furuse K., Kubota K., Kawahara M., et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology. 53:1996;169-172.
61. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer (see comments). New Engl. J. Med. 327:1992;1618-1624.
62. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis (see comments). J. Clin. Oncol. 10:1992;890-895.
63. Lichter A.S., Bunn P.A. Jr, Ihde D.C., et al. The role of radiation therapy in the treatment of small cell lung cancer. Cancer. 55:(Suppl. 9):1985;2163-2175.
64. Perez C.A., Einhorn L., Oldham R.K., et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J. Clin. Oncol. 2:1984;1200-1208.
65. Perry M.C., Eaton W.L., Propert K.J., et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. New Engl. J. Med. 316:1987;912-918.
66. Rosenthal, Tattersa M.H.N., Fox R.M., et al. Adjuvant thoracic radiotherapy in small cell lung cancer: ten-year follow-up of a randomized study. Lung Cancer. 7:1991;235.
67. Perry M.C., Herndon J.E. III, Eaton W.L., Green M.G. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J. Clin. Oncol. 16:1998;2466-2467.
68. Work E., Nielsen O.S., Bentzen S.M., Fode K., Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J. Clin. Oncol. 15:1997;3030-3037.
69. Murray N., Coy P., Pater J.L., et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 11:1993;336-344.
70. Takada M., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol. 20:2002;3054-3060.
71. Jeremic B., Shibamoto Y., Acimovic L. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited stage small cell lung cancer: a randomized study. J. Clin. Oncol. 15:1997;893-900.
72. Gregor A., Drings P., Burghouts J. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J. Clin. Oncol. 15:1997;2840-2849.
73. LeBeau B., Chasting C., Urban T. A randomized clinical trial comparing concurrent versus alternating thoracic irradiation in limited small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;A 383.
74. Curran W.J.J. Combined-modality therapy for limited-stage small cell lung cancer. Semin. Oncol. 28:(Suppl. 4):2001;14-22.
75. Papac R.J., Son Y., Bien R., Tiedemann D., Keohane M., Yesner R. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy [published erratum appears in Int J Radiat Oncol Biol Phys 1988 Jan;14(1):213]. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;993-998.
76. Choi N., Herndon J., Rosenman J. Phase I study to determine the maximum tolerated dose of radiation in standard daily and accelerated twice daily radiotherapy schedules with concurrent chemotherapy for limited stage small lung cancer: CALGB 8837. J. Clin. Oncol. 16:1998;3528-3536.
77. Turrisi A.T. III, Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl. J. Med. 340:1999;265-271.
78. Bonner J.A., Sloan J.A., Shanahan T.G., et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J. Clin. Oncol. 17:1999;2681-2691.
79. Kies M.S., Mira J.G., Crowley J.J., et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J. Clin. Oncol. 5:1987;592-600.
80. Liengswangwong V., Bonner J.A., Shaw E.G., et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J. Clin. Oncol. 12:1994;496-502.
81. Brodin O., Rikner G., Steinholtz L. Local failure in patients treated with radiotherapy and multidrug chemotherapy for small cell lung cancer. Acta Oncol. 29:1990;739-746.
82. Leibel S.A., Fuks Z., Zelefsky M.J., et al. Intensity-modulated radiotherapy. Cancer J. 8:2002;164-176.
83. Bradley J.D., Ieumwananonthachai N., Purdy J.A., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 52:2002;49-57.
84. Argiris A., Murren J.R. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 7:2001;437-447.
85. Nugent J.L., Bunn P.A. Jr, Matthews M.J., et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 44:1979;1885-1893.
86. Pederson A.G., Krisjansen P.E.G., Hansen H.H. Prophylactic cranial irradiation and small cell lung cancer. Cancer Treat. Rev. 15:1988;85-103.
87. Rosen S.T., Makuch R.W., Lichter A.S., et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. Am. J. Med. 74:1983;615-624.
88. Aroney R.S., Aisner J., Wesley M.N., et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat. Rep. 67:1983;675-682.
89. Auperin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group (see comments). New Engl. J. Med. 341:1999;476-484.
90. Fleck J.F., Einhorn L.H., Lauer R.C., Schultz S.M., Miller M.E. Is prophylactic cranial irradiation indicated in small-cell lung cancer. J. Clin. Oncol. 8:1990;209-214.
91. Laukkanen E., Klonoff H., Allan B., Graeb D., Murray N. The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae. Int. J. Radiat. Oncol. Biol. Phys. 14:1988;1109-1117.
92. Johnson B.E., Becker B., Goff W.B.D., et al. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J. Clin. Oncol. 3:1985;1659-1667.
93. Arriagada R., Le Chevalier T., Borie F. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer Inst. 87:1995;183-190.
94. Gurney H., Dodwell D., Thatcher N. Escalating drug delivery in cancer therapy: a review of concepts and practice. Ann. Oncol. 4:1993;103-115.
95. Klasa R.J., Murray N., Coldman A.J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol. 9:1991;499-508.
96. Johnson D.H., Einhorn L.H., Birch R., et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 5:1987;1731-1738.
97. Ihde D.C., Mulshine J.L., Kramer B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12:1994;2022-2034.
98. Arriagada R., Le Chevalier T., Pignon J.P., et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. New Engl. J. Med. 329:1993;1848-1852.
99. Le Chevalier T., Riviere A., Pignon J., et al. Is there an optimal dose for frontline chemotherapy (CT) in limited small cell lung cancer (SCLC)? Results of a randomized trial in 295 patients from the French Cancer Centers Group. Proc. Am. Soc. Clin. Oncol. 2002;A 1172.
100. Steward W.P., von Pawel J., Gatzemeier U., et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J. Clin. Oncol. 16:1998;642-650.
101. Ardizzoni A., Tjan-Heijnen V.C.G., Postmus P.E., et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial - 08923. J. Clin. Oncol. 20:2002;3947-3955.
102. Thatcher N., Girling D.J., Hopwood P., Sambrook R.J., Qian W., Stephens R.J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J. Clin. Oncol. 18:2000;395-404.
103. Bunn P.A. Jr, Crowley J., Kelly K., et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group [published erratum appears in J. Clin. Oncol. 1995 Nov;13(11):2860]. J. Clin. Oncol. 13:1995;1632-1641.
104. Humblet Y., Symann M., Bosly A., et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J. Clin. Oncol. 5:1987;1864-1873.
105. Goodman G.E., Crowley J., Livingston R.B., Rivkin S.E., Albain K., McCulloch J.H. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. J. Clin. Oncol. 9:1991;453-457.
106. Elias A. Dose-intensive therapy in small cell lung cancer. Chest. 113:1998;101S-106S.
107. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest. 116:1999;531S-538S.
108. Elias A.D., Ayash L., Frei E.D., et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J. Natl. Cancer Inst. 85:1993;559-566.
109. Elias A. Dose intensification of chemotherapy in SCLC: pro. contoversies in lung cancer, a multidisciplinary approach by B. Movsas et al. 2001;91-106 Marcel Dekker.
110. Leyvraz S., Perey L., Rosti G., et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 17:1999;3531-3539.
111. Krug L.M., Grant S.C., Miller V.A., Ng K.K., Kris M.G. Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. Semin. Oncol. 26:(Suppl. 15):1999;55-61.
112. Jett J.R., Maksymiuk A.W., Su J.Q., et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J. Clin. Oncol. 12:1994;2321-2326.
113. Kelly K., Crowley J.J., Bunn P.A. Jr, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J. Clin. Oncol. 13:1995;2924-2930.
114. Grant S.C., Kris M.G., Houghton A.N., Chapman P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. 5:1999;1319-1323.
115. Mulshine J.L., Avis I., Treston A.M., et al. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann. New York Acad. Sci. 547:1988;360-372.
116. Nakanishi Y., Mulshine J.L., Kasprzyk P.G. Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J. Clin. Invest. 82:1988;354-359.
117. Johnson B.E., Kelley M.J. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest. 103:1993;15-35.
118. Fiorentini C., Facchetti M., Finardi A., et al. Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. Eur. J. Endocrinol. 147:2002;371-379.
119. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 56:1996;370-376.
120. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6:2000;3319-3326.
121. Wang W.L., Healy M.E., Sattler M., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19:2000;3521-3528.
122. Johnson B.E., Fisher B., Fisher T., et al. Phase II study of STI571 (Gleevec™) for patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 2002;A 1171.
123. Rudin C., Otterson G.A., Mauer A.M., et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 13:2002;539-545.
124. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2002;2387-2392.
125. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastases. J. Natl. Cancer Inst. 89:1997;1260-1270.
126. Shepherd F.A., Giaccone C., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20:2002;4434-4439.
127. Shepherd F.A. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin. Oncol. 28:2001;30-37.